Drug discovery in the kinase inhibitory field using the nested chemical library™ technology

Assay and Drug Development Technologies

Volumn 3, Issue 5, 2005, Pages 543-551

  Kéri, György ^a,b   Székelyhidi, Zsolt ^a   Bánhegyi, Péter ^a   Varga, Zoltán ^a   Hegymegi Barakonyi, Bálint ^a   Szántai Kis, Csaba ^a   Hafenbradl, Doris ^c   Klebl, Bert ^c   Muller, Gerhard ^c   Ullrich, Axel ^d   Erös, Dániel ^b   Horváth, Zoltán ^b   Greff, Zoltán ^b   Marosfalvi, Jenö ^b   Pató, János ^b   Szabadkai, István ^b   Szilágyi, Ildikó ^b   Szegedi, Zsolt ^b   Varga, István ^b   Wáczek, Frigyes ^a   Örfi, László ^a,b   more..

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Vichem Chemie Ltd   (Hungary)

^c GPC Biotech AG   (Germany)

^d MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; LEAD; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; QUINOXALINE DERIVATIVE; RECEPTOR INTERACTING PROTEIN 140; RHO KINASE; VASCULOTROPIN RECEPTOR;

ANTIVIRAL ACTIVITY; COMPUTER AIDED DESIGN; COMPUTER MODEL; DATA BASE; DRUG DESIGN; DRUG RESEARCH; DRUG STRUCTURE; ENZYME ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; INHIBITION KINETICS; LIBRARY; MOLECULAR CLONING; PHARMACOPHORE; PROCESS OPTIMIZATION; PROTEIN TARGETING; QUANTITATIVE STRUCTURE PROPERTY RELATION; REVIEW; STRUCTURE ANALYSIS; VALIDATION PROCESS; X RAY;

ALGORITHMS; CHEMISTRY, PHARMACEUTICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DATABASES, FACTUAL; DRUG DESIGN; PHARMACEUTICAL PREPARATIONS; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 29244443386     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2005.3.543     Document Type: Review

References (44)

1. Hanash S: Disease proteomics. Nature 2003;422:226-232.
2. Levitzki A: Signal transduction therapy - a novel-approach to disease management. Eur J Biochem 1994;226:1-13.
3. Hollósy F, Mészáros G, Bökönyi G, Idei M, Seprödi A, Szende B, Kéri Gy: Cytostatic, cytotoxic and protein tyrosine kinase inhibitory activity of ursolic acid in A431 human tumor cells. Anticancer Res 2000;20:4563-4570.
4. Kéri Gy, Rácz G, Magyar K, Örfi L, Horváth A, Schwáb R, Hegymegi BB, Szende B: Pro-apoptotic and anti-apoptotic molecules affecting pathways of signal transduction. Ann N Y Acad Sci 2003;1010:109-112.
5. Deininger MW, Goldman JM, Lydon N, Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691-3698.
6. Goldman JM: Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia. Lancet 2000;355:1031-1032.
7. Klebl BM, Müller G: Second-generation kinase inhibitors. Exp Opin Ther Targets 2005;9 (in press).
8. Dancey J, Sausville EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2:296-313.
9. Kolibaba KS, Druker BJ: Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997;1333:F217-F248.
10. Laird AD, Cherrington JM: Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs 2003;12:51-64.
11. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Kéri Gy, Örfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK: Flk-1 as a target for tumor growth inhibition. Cancer Res 1996;56:3540-3545.
12. Hirth KP, Schwartz DP, Mann E, Shawver LK, Kéri Gy, Örfi L, Székely I, Bajor T, Haimichael J, Örfi L, Levitzki A, Gazit A, Ullrich A, Lammers R, Kabbinavar FF, Slamon D, Tang TC, inventors; Sugen Inc., assignee: Treatment of platelet derived growth factor related disorders such as cancers. US patent 5,990,141. November 23, 1999.
13. Morimoto AM, Tan N, West K, McArthur G, Toner GC, Manning WC, Smolich BD, Cherrington JM: Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene 2004;23:1618-1626.
14. Beroza P, Villar HO, Wick MM, Martin GR: Chemoproteomics as a basis for post genomic drug discovery. Drug Discov Today 2002;7:807-814.
15. Erös D, Örfi L, Kéri Gy: Rational drug design and signal transduction therapy. Pharmachem 2004;1:27-30.
16. Bhattacharya SK, Cox ED, Kath JC, Mathiowetz AM, Morris J, Moyer JD, Pustilnik LR, Rafidi K, Richter DT, Su C, Wessel MD: Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor. Biochem Biophys Res Commun 2003;307:267-273.
17. Breitenlechner C, Gaßel M, Hidaka, H, Kinzel V, Huber R, Engh RA, Bossemeyer D: Protein kinase A in complex with rho-kinase inhibitors Y-27632, fasudil, and H-1152P: structural basis of selectivity. Structure 2003;11:1595-1607.
18. Burchat AF, Calderwood DJ, Friedman MM, Hirst GC, Li B, Rafferty P, Ritter K, Skinner BS: Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck - a selectivity insight. Bioorg Med Chem Lett 2002;12:1687-1690.
19. Scapin G: Structural biology in drug design: selective protein kinase inhibitors. Drug Discov Today 2002;7:601-611.
20. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Müller S, Klebl B, Cotten M, Kéri Gy, Wissing J, Daub H: Cellular targets of Gefitinib. Cancer Res 2005; 65:379-382.
21. Godl K, Gruss OG, Eickhoff J, Wissing J, Blencke S, Weber M, Gutbrod H, Brehmer D, Horváth Z, Kéri Gy, Cotten M, Müller S, Ullrich A, Daub H: Proteomic characterization of the anticancer drug SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res 2005; 65:6919-6926.
22. Örfi L, Wáczek F, Kövesdi I, Mészáros Gy, Idei M, Horváth A, Hollósy F, Mak M, Szegedi Z, Szende B, Kéri Gy: New antitumor leads from a peptidomimetic library. Lett Peptide Sci 1999;6:325-333.
23. Klebl BM: Chemical kinomics: a target gene family approach in chemical biology. Drug Discov Today Technol 2004;1:25-34.
24. Klebl BM, Daub H, Kéri Gy: Chemical kinomics. In: Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective. Kubinyi H, Müller G (eds.), pp. 167-190. Wiley-VCH, Weinheim, 2004.
25. Erös D, Kövesdi I, Örfi L, Takács-Novák K, Acsády Gy, Kéri Gy: Reliability of logP predictions based on calculated moleular descriptors: a critical review. Curr Med Chem 2002;9:1819-1829.
26. Erös D, Kéri Gy, Kövesdi I, Szántai-Kis Cs, Mészáros Gy, Örfi L: Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods. Mini Rev Med Chem 2004;4:167-177.
27. Kövesdi I, Kéri Gy, Örfi L: Method for generating a quantitative structure property activity relationship. US patent application 20040199334 A1. October 7, 2004.
28. Koul A, Klebl B, Mueller G, Missio A, Schwab W, Hafenbradl D, Neumann L, Sommer M-N, Mueller S, Hoppe E, Freisleben A, Backes A, Hartung C, Felber B, Zech B, Engkvist O, Kéri Gy, Örfi L, Bánhegyi P, Greff Z, Horváth Z, Varga Z, Markó P, Pató J, Szabadkai I, Székelyhidi Z, Wáczek F: Heterobicyclic compounds as pharmaceutically active agents. WO patent 2005/023818 A2. March 17, 2005.
29. Blencke S, Zech B, Engkvist O, Greff Z, Örfi L, Horváth Z, Kéri Gy, Ullrich A, Daub H: Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 2004;11: 691-701.
30. Godl K, Missio A, Daub H, Stein-Gerlach M, Greff Z: Medium and method for enriching, purifying or depleting ATP binding proteins from a pool of proteins. WO patent 2004/013633 A2. February 12, 2004.
31. Pató J, Kéri Gy, Örfi L, Wáczek F, Horváth Z, Bánhegyi P, Szabadkai I, Marosfalvi J, Hegymegi-Barakonyi B, Székelyhidi Zs, Greff Z, Choidas A, Bacher G, Daub H, Obert S, Kurtenbach A, Habenberger P: Benzo[g]quinoxaline derivatives as effective compounds against infectious diseases. WO patent 02/094796 A2. November 28, 2002.
32. 3H-quinazolin-4-ones, the key intermediates of recently developed drugs. Curr Med Chem 2004;11:2549-2553.
33. Pató J, Kéri Gy, Örfi L, Wáczek F, Horváth Z, Bánhegyi P, Szabadkai I, Marosfalvi J, Hegymegi-Barakonyi B, Székelyhidi Zs, Greff Z, Choidas A, Bacher G, Missio A, Koul A: Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor. US patent application 2004/0171603 A1. September 2, 2004.
34. Carta A, Loriga M, Zanetti S, Sechi LA: Quinoxalin-2-ones. Part 5. Synthesis and antimicrobial evaluation of 3-alkyl-, 3-halomethyl- and 3-carboxyethylquinoxaline-2-ones variously substituted on the benzo-moiety. Farmaco 2003;58:1251-1255.
35. Brown MF, Avery M, Brissette WH, Chang JH, Colizza K, Conklyn M, DiRico AP, Gladue RP, Krueger SS, Lira PD, Lillie BM, Lundquist GD, Mairs EN, McElroy EB, McGlynn MA, Paradis TJ, Poss CS, Rossulek MI, Shepard RM, Smiths J, Strelevitz TJ, Truesdell S, Tylaska LA, Yoon K, Zheng D: Novel CCR1 antagonists with improved metabolic stability. Bioorg Med Chem Lett 2004;14:2175-2179.
36. Hazeldine ST, Polin L, Kushner J, Paluch J, White K, Edelstein M, Palomino E, Corbett TH, Horwitz JP: Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy) propionic acid (XK469). J Med Chem 2001;44:1758-1776.
37. Myers M, He W, Hanney B, Setzer N, Maguire M, Zulli A, Bilder G, Galzcinski H, Amin D, Needle S, Spada A: Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR exploration and elective bioisosteric replacement of a phenyl substituent. Bioorg Med Chem Lett 2003;13:3091-3095.
38. He W, Myers M, Hanney B, Spada A, Bilder G, Galzcinski H, Amin D, Needle S, Page K, Jayyosi Z, Perrone M: Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: The synthesis and biological activities of RPR127963 an orally bioavailable inhibitor. Bioorg Med Chem Lett 2003;13:3097-3100.
39. Gazit A, App H, McMahon G, Chen J, Levitzki A, Bohmer F: Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: Structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. J Med Chem 1996;39:2170-2177.
40. Valko K, Bevan C, Reynolds D: Chromatographic hydrophobicity index by fast-gradient RP-HPLC: a high-throughput alternative to log P/log D. Anal Chem 1997;69: 2022-2029.
41. Erös D, Kövesdi I, Örfi L, Takács-Novák K, Acsády Gy, Kéri Gy: Reliability of logP predictions based on calculated molecular descriptors: a critical review. Curr Med Chem 2002;9:1819-1829.
42. Erös D, Kéri Gy, Kövesdi I, Szántai-Kis Cs, Mészáros Gy, Örfi L: Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods. Mini Rev Med Chem 2004;4:167-177.
43. Kövesdi I, Kéri Gy, Örfi L: Method for generating a quantitative structure property activity relationship. WO Patent 02/082329 A2. October 17, 2002.
44. Székelyhidi Z, Pató J, Wáczek F, Bánhegyi P, Hegymegi-Barakonyi B, Erös D, Mészáros Gy, Hollósy F, Hafenbradl D, Obert S, Klebl B, Kéri Gy, Örfi L: Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives. Bioorg Med Chem Lett 2005;15:3241-3246.